Findings for the Combination of Anti-TIM-3 and Anti-PD-1 in Melanoma and Lung Cancer

December 27, 2018
Diwakar Davar, MBBS, MSc

Diwakar Davar, MBBS, MSc, discusses how data from the phase I trial of TSR-022, an anti-TIM-3 monoclonal antibody, and TSR-042, an anti-PD-1 agent, impact the treatment of patients with both melanoma and lung cancer.

Diwakar Davar, MBBS, MSc, assistant professor of medicine and medical oncologist/hematologist at UPMC Hillman Cancer Center, discusses how data from a phase I trial of TSR-022, an anti-TIM-3 monoclonal antibody, and TSR-042, an anti-PD-1 agent, impact the treatment of patients with both melanoma and lung cancer.

PD-1 checkpoint inhibition has been dominant in the treatment paradigm, says Davar, as it produces significant responses in both disease settings. According to these data, this combination is both safe and efficacious in patients who are refractory to PD-1.